Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal transduction system, are long-established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a particularly high number of clinical trials involving PDE inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bondarev, Andrey D., Attwood, Misty M., Jonsson, Jörgen, Chubarev, Vladimir N., Tarasov, Vadim V., Liu, Wen, Schiöth, Helgi B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731127/
https://www.ncbi.nlm.nih.gov/pubmed/36506513
http://dx.doi.org/10.3389/fphar.2022.1057083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731127/
https://www.ncbi.nlm.nih.gov/pubmed/36506513
http://dx.doi.org/10.3389/fphar.2022.1057083

Ejemplares similares